Table 1.
Demographic, clinical and parasitological characteristics of study participants.
Fig 1.
Age trends in P. falciparum and P. vivax blood-stage and gametocyte prevalence and density.
Error bars represent CI95.
Table 2.
Multivariate predictors of P. falciparum parasite prevalence and proportion of gametocyte positive.
Table 3.
Multivariate predictors of P. vivax parasite prevalence and proportion gametocyte positive.
Fig 2.
pvs25 transcript numbers versus light microscopically determined P. vivax gametocyte counts.
Dilution series were made before storing samples in RNAprotect (5 dilution steps) or after RNA extraction of samples stored in TRIzol (3 dilution steps). Dots represent means of technical triplicates (TRIzol) or quintuplicates (RNAprotect) of dilutions except for the highest concentration (no replicates). Shaded grey shows the CI95 of the intercept of the regression of compiled sample sets.
Fig 3.
Relationship between parasite density and probability that a sample is gametocyte positive.
Left: Probability (with CI95) that a sample is gametocyte positive vs. parasite density, calculated using a general additive model. Right: correlation between gametocyte density (measured as pfs25 or pvs25 transcripts/uL) and parasite density by qPCR.
Table 4.
Determinants of P. falciparum and P. vivax gametocyte density.